STOCK TITAN

Elanco Animal Health Incorporated - ELAN STOCK NEWS

Welcome to our dedicated page for Elanco Animal Health Incorporated news (Ticker: ELAN), a resource for investors and traders seeking the latest updates and insights on Elanco Animal Health Incorporated stock.

Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health, committed to innovating and delivering products and services to improve the health and wellness of both farm animals and pets. Established with nearly 70 years of heritage, Elanco operates in over 90 countries with a diverse portfolio of approximately 200 brands. Their core mission is encapsulated in their vision: 'Food and Companionship Enriching Life,' which they pursue through three primary avenues:

  • Enhancing food security by improving the health and productivity of farm animals, thereby contributing to a safer, more affordable, and abundant food supply.
  • Helping pets live longer, healthier lives through advanced veterinary products.
  • Improving food safety standards globally.

Elanco’s dedication to animal health is reflected in their continuous innovation and quality systems, driven by a shared vision of enhancing life for animals and humans alike. This commitment is evident in their recent achievements and ongoing projects. For instance, Elanco's collaboration with Agtech company, Cattler, aims to provide data-driven solutions to cattle farmers, enhancing operational efficiency and productivity through services like Benchmark™ and Experior™.

Elanco's financial health is strong, with the company reporting consistent revenue growth and strategic investments aimed at future expansion. In their recent financial results, Elanco posted a 5% growth in the fourth quarter and strengthened their commercial infrastructure to support ongoing and future growth. They also announced the divestiture of their aqua business to streamline operations and focus on core areas, which is expected to reduce their debt leverage significantly by year-end.

Environmental sustainability is another critical focus for Elanco. Their recent partnership with Athian to create a livestock carbon insetting marketplace is a significant step towards reducing greenhouse gas emissions in the dairy and beef industries. Products like Bovaer®, which significantly reduce methane emissions from cattle, exemplify Elanco's commitment to sustainable farming practices.

Overall, Elanco continues to be at the forefront of animal health innovation, with substantial investments in R&D, strategic partnerships, and a clear commitment to sustainability and community health.

Rhea-AI Summary
Elanco Animal Health's CEO, Jeff Simmons, discussed the company's pipeline with six potential blockbuster products and the launch of a USDA conditionally-approved therapeutic solution for canine parvovirus on Mad Money. The company also announced a campaign to save 1 million puppies from parvo, aiming to increase education about the disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.5%
Tags
none
-
Rhea-AI Summary
Merck Animal Health, a division of Merck & Co., Inc., is set to acquire the aqua business of Elanco Animal Health Incorporated for $1.3 billion in cash, expanding its aqua portfolio with innovative products and technology solutions. The acquisition includes aqua manufacturing facilities, a research facility, and a portfolio of medicines, vaccines, and supplements for aquatic species. The deal is expected to be completed by mid-year 2024, subject to regulatory approvals and customary closing conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.94%
Tags
-
Rhea-AI Summary
Elanco Animal Health Incorporated (NYSE: ELAN) announced the sale of its aqua business to Merck Animal Health (NYSE: MRK) for approximately $1.3 billion in cash, reinforcing its focus on pet health and livestock sustainability. The transaction will enable Elanco to accelerate debt paydown by $1.05B to $1.1B, with net debt to adjusted EBITDA expected in the high-3x to low-4x range by the end of 2025. The aqua business generated an estimated $175 million in revenue and approximately $92 million in adjusted EBITDA in 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.94%
Tags
none
Rhea-AI Summary
Elanco Animal Health Incorporated (NYSE: ELAN) has launched a multi-year campaign to save 1 million puppies from deadly canine parvovirus. The 'Defend Puppies. Defeat Parvo.' mission aims to conquer a virus with a 91% mortality rate, affecting an estimated 900 dogs daily in the U.S. Elanco seeks to increase education and awareness to protect puppies from this highly contagious disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.18%
Tags
none
-
Rhea-AI Summary
The 2024 Feather in Her Cap awards ceremony honored 11 women for their outstanding career achievements in Animal Health, including Andrea J. Gonzales, Ph.D., of Zoetis, Inc. (NYSE: ZTS), and Katharina Bohnenblust, Ph.D., of Elanco Animal Health (NYSE: ELAN). Dr. Gonzales, Vice President of Global Companion Animal Therapeutics at Zoetis, was recognized for her leadership and contributions to the industry, while Dr. Bohnenblust received the 2024 High Flyer award for her accomplishments in pharmaceutical development. The awards aim to inspire the next generation of industry leaders and recognize women's achievements in Animal Health. Dr. Gonzales' passion for building an innovative R&D pipeline of animal health therapeutics and her commitment to mentoring women in the industry were highlighted, and she chose Cheff Therapeutic Riding Center in Kalamazoo, Michigan, as the recipient of a $5,000 charitable donation. Dr. Bohnenblust, who serves as a mentor for young female scientists, developed the new Elanco JAK-inhibitor formulation and manufacturing process. The Feather in Her Cap Association will reopen the nomination process in Q3 of 2024 to celebrate more outstanding women in Animal Health in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.7%
Tags
none
-
Rhea-AI Summary
Elanco Animal Health Incorporated (NYSE: ELAN) announced Lawrence E. Kurzius as the next Chairman of the Board, effective at the conclusion of the Company's 2024 Annual Meeting of Shareholders. The Board plans to rotate committee leadership and seek shareholder approval to modify the voting standard for uncontested director elections.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.74%
Tags
management
Rhea-AI Summary
Elanco Animal Health Incorporated (NYSE: ELAN) to Participate in 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.54%
Tags
conferences
-
Rhea-AI Summary
Alveolus Bio (ALVB) announced a strategic scientific collaboration with BiomEdit, an animal health biotechnology company leveraging microbiome science and synthetic biology to develop novel products to prevent and treat disease in animals. The collaboration aims to study BiomEdit's proprietary consortium of commensal strains with anti-inflammatory and immune-modulating properties, as well as to explore the application of Alveolus Bio's resMIT platform for the development of respiratory therapeutics in companion animals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.26%
Tags
none
-
Rhea-AI Summary
Elanco Animal Health Incorporated (ELAN) to attend Evercore ISI 6th Annual HealthCONx Conference on November 28-29, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
conferences
Rhea-AI Summary
Ziff Davis, Inc. (NASDAQ: ZD) appoints Kirk McDonald to its Board of Directors, effective November 15, 2023. McDonald, a highly accomplished executive with extensive experience in media, technology, and advertising, will bring valuable business leadership to Ziff Davis. He currently serves as CEO of GroupM North America and will leave the role at year end. With a career spanning over three decades, McDonald has held executive level leadership roles at prominent companies such as Warner Media's Xandr, Pubmatic, Time Inc., the Aquantive division of Microsoft, and CNET Networks. He also serves on the board of Elanco (NYSE: ELAN) and is a founding member of the Black Executive CMO Alliance. Kirk McDonald is widely respected in the industry and known for his leadership and innovation in the media and advertising ecosystem.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.87%
Tags
management

FAQ

What is the current stock price of Elanco Animal Health Incorporated (ELAN)?

The current stock price of Elanco Animal Health Incorporated (ELAN) is $13.98 as of November 15, 2024.

What is the market cap of Elanco Animal Health Incorporated (ELAN)?

The market cap of Elanco Animal Health Incorporated (ELAN) is approximately 6.8B.

What is Elanco Animal Health's core mission?

Elanco's core mission is encapsulated in their vision: 'Food and Companionship Enriching Life,' which they pursue by enhancing food security, improving pet health, and elevating food safety standards globally.

In how many countries does Elanco operate?

Elanco operates in over 90 countries worldwide.

What recent collaborations has Elanco engaged in?

Elanco recently collaborated with Agtech company Cattler to provide data-driven solutions to cattle farmers through services like Benchmark™ and Experior™.

What is the significance of Elanco's partnership with Athian?

The partnership with Athian aims to create a livestock carbon insetting marketplace, reducing greenhouse gas emissions and promoting sustainable farming practices.

What are some of Elanco's notable products?

Elanco's notable products include Seresto®, Experior™, and Bovaer®, the latter being a methane-reducing feed ingredient for cattle.

How is Elanco addressing sustainability in animal farming?

Elanco addresses sustainability through innovative products like Bovaer®, which reduces methane emissions from cattle, and partnerships aimed at creating carbon insetting marketplaces.

What financial goals has Elanco set for 2024?

Elanco expects constant currency revenue growth of 2% to 3% for 2024, driven by new product launches and operational improvements. They also anticipate significant debt reduction through strategic divestitures.

How does Elanco contribute to food safety?

Elanco contributes to food safety by developing products that improve the health and performance of farm animals, thereby ensuring a safer and more reliable food supply.

What is Elanco's approach to innovation?

Elanco's approach to innovation involves continuous R&D investments, strategic partnerships, and the development of new products that address pressing issues in animal health and sustainability.

How does Elanco support the health and wellness of pets?

Elanco supports pet health through an extensive range of veterinary products designed to improve the quality and longevity of pets' lives.

Elanco Animal Health Incorporated

NYSE:ELAN

ELAN Rankings

ELAN Stock Data

6.81B
494.35M
0.66%
100.35%
2.33%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
GREENFIELD